We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.75 | 8.50 | 9.00 | 8.75 | 8.75 | 8.75 | 6,800 | 07:33:41 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMIXI
RNS Number : 6086B
IXICO plc
21 September 2018
The following amendment has been made to the 'Results of General Meeting' announcement released on 21/09/2018 at 11:00 under RNS No 5577B.
Updated contact details.
All other details remain unchanged.
The full amended text is shown below.
IXICO plc
("IXICO" or the "Company")
Result of General Meeting
IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, is pleased to announce that at the General Meeting held earlier today, the Resolutions to approve the Capital Reorganisation were duly passed.
Application has been made to AIM for the New Ordinary Shares to be admitted to trading on AIM. It is expected that such Admission will become effective and that dealings will commence in the New Ordinary Shares at 8.00 am on 24 September 2018.
Following Admission the Company's issued share capital will consist of 46,777,000 New Ordinary Shares of 1 pence each. The total number of voting rights in the Company will therefore be 46,777,000 New Ordinary Shares.
Unless otherwise stated, defined terms in this announcement not otherwise defined shall have the same meaning as is ascribed to them in the circular posted to shareholders on 3 September 2018.
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Officer Tel: +44 20 3763 Susan Lowther, Chief Financial Officer 7499 Shore Capital (Nomad and Broker) Tel: +44 20 7408 Edward Mansfield / Anita Ghanekar / Daniel 4090 Bush FTI Consulting Limited (Investor Relations) Tel: +44 20 3727 Simon Conway/Mo Noonan 1000
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our clients' neurodegenerative therapeutic pipeline through the application of novel medical imaging and mobile health digital technologies.
IXICO's specialist data analytics services are used by the global pharmaceutical industry to interpret brain scan data and digital biomarkers to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical trial process evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ROMLLFVEASILFIT
(END) Dow Jones Newswires
September 21, 2018 11:46 ET (15:46 GMT)
1 Year Ixico Chart |
1 Month Ixico Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
